| Literature DB >> 34620843 |
Wenjuan Ma1, Yuxi Zhan1, Yuxin Zhang1, Chenchen Mao1, Xueping Xie1, Yunfeng Lin2,3.
Abstract
DNA, a genetic material, has been employed in different scientific directions for various biological applications as driven by DNA nanotechnology in the past decades, including tissue regeneration, disease prevention, inflammation inhibition, bioimaging, biosensing, diagnosis, antitumor drug delivery, and therapeutics. With the rapid progress in DNA nanotechnology, multitudinous DNA nanomaterials have been designed with different shape and size based on the classic Watson-Crick base-pairing for molecular self-assembly. Some DNA materials could functionally change cell biological behaviors, such as cell migration, cell proliferation, cell differentiation, autophagy, and anti-inflammatory effects. Some single-stranded DNAs (ssDNAs) or RNAs with secondary structures via self-pairing, named aptamer, possess the ability of targeting, which are selected by systematic evolution of ligands by exponential enrichment (SELEX) and applied for tumor targeted diagnosis and treatment. Some DNA nanomaterials with three-dimensional (3D) nanostructures and stable structures are investigated as drug carrier systems to delivery multiple antitumor medicine or gene therapeutic agents. While the functional DNA nanostructures have promoted the development of the DNA nanotechnology with innovative designs and preparation strategies, and also proved with great potential in the biological and medical use, there is still a long way to go for the eventual application of DNA materials in real life. Here in this review, we conducted a comprehensive survey of the structural development history of various DNA nanomaterials, introduced the principles of different DNA nanomaterials, summarized their biological applications in different fields, and discussed the current challenges and further directions that could help to achieve their applications in the future.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34620843 PMCID: PMC8497566 DOI: 10.1038/s41392-021-00727-9
Source DB: PubMed Journal: Signal Transduct Target Ther ISSN: 2059-3635
Fig. 1The biological applications of various DNA-based and DNA-encoding nanomaterials in tissue engineering. a, f The biological applications of different DNA-based nanomaterials in neural tissue (e.g., TDNs, NPs loading various pDNA, polycation loading various pDNA, and some nanofibrous loading pDNA). b The biological applications of different DNA-based nanomaterials in skin tissue (e.g., TDNs, polycation loading various pDNA, and some basement materials loading pDNA). c, e The biological applications of different DNA-based nanomaterials in skeletal and cardiac muscle engineering (e.g., skeletal tissue: NIR-DA, NPs loading genomic DNA, and various polycation loading pDNA; cardiac muscle: nanofibrous loading pDNA and TDNs). d The biological applications of different DNA-based nanomaterials in corneal tissue (e.g., TDNs, NPs loading various pDNA, and polycation loading various pDNA). g The biological applications of different DNA-based nanomaterials in bone tissue engineering (e.g., TDNs, LNPs loading pDNA, polypeptides loading various pDNA, and polycation loading various pDNA)
The biological applications of various DNA-based and DNA-encoding nanomaterials in tissue engineering
| Tissue regeneration engineering | Material format | Composition | DNA nanotructure | Biological function | References |
|---|---|---|---|---|---|
| Bone tissue regeneration | DNA/chitosan nanoparticles | 1. Poly( 2. pDNA/ | pDNA/ | PLGA/HAp composite scaffolds could deliver the pDNA/ | [ |
1. PEI 2. Human pDNA/ | Human pDNA/ | Bone formation. | [ | ||
| DNA-loaded calcium phosphate nanoparticles | 1. Nano-calcium phosphate paste 2. pDNA/ 3. pDNA/ | 1. pDNA/ 2 pDNA/ | Enhanced regeneration of bone volume and a significantly faster healing. | [ | |
| Chitosan-gold nanoparticles mediated gene delivery of | 1. Chitosan-gold nanoparticles 2. pDNA/ | pDNA/ | Suppressing osteoclastogenesis and promoting osteogenesis of dental implant even in osteoporotic condition | [ | |
| CS/CSn(pDNA/ | 1. chitosan (CS)-based hydrogel with a,b-glycerophosphate (a,b-GP) 2. pDNA/ | pDNA/ | Enhancing cell proliferation, maintaining great potential in gene delivery system and tissue regeneration of periodontium | [ | |
| Chitosan/β-glycerophosphate (CS/β-GP) hydrogel as a | 1. Chitosan/β-glycerophosphate (CS/β-GP) hydrogel 2. | Delivering and releasing | [ | ||
| Lipopolysaccharide-amine nanopolymersomes (LNPs) modified with | 1. Lipopolysaccharide-amine nanopolymersomes 2. 3. pDNA/ | 1. 2. pDNA/ | Enhancing osteogenic differentiation. | [ | |
| Star-shaped poly( | 1. Star-shaped poly( 2. pDNA/ | 1. pDNA/ 2. pDNA/ | Irritating mesenchymal stem cells (MSCs) to differentiate into bone tissue. | [ | |
| DNA/protamine complex scaffold | 1. Protamine 2. pDNA/ | 1. pDNA/ 2. pDNA/ | Enhancement of bone regeneration, and gene delivery. | [ | |
| Tetrahedral DNA nanostructures (TDNs) | TDNs | TDNs | Enhancing the cell growth and motility of different cells, such as adipose stem cells (ASCs), human periodontal ligament stem cells (PDLSCs), MSCs, and chondrocytes. TDNs could act the anti-inflammatory effects on the periodontist model, and could promote osteogenic differentiation | [ | |
| TDNs/Wogonin | 1. TDNs 2. Wogonin | TDNs | Enhancing expression of chondrogenic markers, downregulating matrix metalloproteinases and inflammatory mediators, and promoting the expression of tissue inhibitor of metalloproteinase 1 and B-cell lymphoma 2. | [ | |
| Neural tissue engineering | Nanofibrous modified with pDNA | 1. A nanofibrous micro cell carrier 2. A self-assembled nano-sized polymer 3. pDNA/ | pDNA/ | Promoting intervertebral disc (IVD) regeneration and suppress the fibrosis. | [ |
| A novel DNA-based chemical approach with the synthetic DNA-binding inhibitor | Pyrrole-imidazole polyamides (PIPs) | N/A | Targeting cell differentiation controlling genes of human induced pluripotent stem cells (hiPSCs), and the DNA-binding inhibitor could target the | [ | |
| DNA aptamer | yly12 aptamer | yly12 aptamer | The aptamer yly12 could bind neural cell adhesion molecule L1 (L1CAM), which was expressed in normal neural tissue as surface antigen. | [ | |
| Poly(lactide-co-glycolide) (PLG) delivery DNA complexes | 1. PLG 2. pDNA | pDNA | Promoting the transgene expression and the regeneration of complicated neural system. | [ | |
| Nanoparticles loading pDNA and RNA | 1. Nanoparticles 2. pDNA or RNA (e.g., siRNA) | 1. pDNA 2. RNA (e.g., siRNA) | Delivering genetic materials into neural stem cells (NSCs) and guiding cell differentiation. | [ | |
| TDNs | TDNs | TDNs | 1. Enhancing cell proliferation, migration, and neuronal differentiation of NSCs. 2. Improving the recovery of motor function and the neural tissue regeneration in the injured site of spine cord. 3. Potential neuroprotective effects on the cell models of Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). | [ | |
| Skeletal and cardiac muscle engineering | Near-infrared light-activated DNA agonist (NIR-DA) nanodevice | 1. Nongenetic manipulation 2. DNA agonist | DNA agonist | Delivering the cell signaling and regulating the receptor tyrosine kinase (RTK) signaling, cell migration, and myogenesis of skeletal muscle satellite cells. | [ |
| Iron-oxide nanoparticles loading genomic DNA | 1. Magnetic nanoparticle 2. Genomic DNA | Genomic DNA | Capturing some chemotherapy agents from human serum, including cisplatin, epirubicin, and doxorubicin (DOX), and protecting cultured cardiac myoblasts from the lethal levels of chemotherapy agents | [ | |
| TDNs | TDNs | TDNs | Cardio-protection effects from myocardial ischemia-reperfusion injury (MIRI) by taking the advantage of the anti-inflammatory and antioxidative potential. | [ | |
| Skin tissue engineering | N,N,N-trimethyl chitosan chloride (TMC)/pDNA- | 1. TMC 2. pDNA- | pDNA- | Promoting the expression of | [ |
| Collagen-chitosan scaffold/silicone membrane bilayer dermal equivalent (BDE)/ pDNA- | 1. BDE 2. pDNA- | pDNA- | Effective transfection abilities to promote the expression of | [ | |
| Hydrogel embedded with resveratrol (Res) and pDNA- | 1. Gel-Res 2. pDNA- | pDNA- | Promoting the healing of splinted excisional burn wounds. | [ | |
| Nanofibers loading pDNA- | 1. PLLA/POSS 2. pDNA- 3. pDNA- | 1. pDNA- 2. pDNA- | Promoting revascularization of the deep skin defect healing. | [ | |
| Electrospun core-sheath fibers loaded with pDNA- | 1. Electrospun core-sheath fibers 2. pDNA- | pDNA- | Promoting skin regeneration in diabetic rats. | [ | |
| TDNs | TDNs | TDNs | 1. TDNs (sizes ≤ 75 nm) could effectively penetrate the skin of mice and human, and reach dermis layer, which could load and deliver DOX to subcutaneous tumor site. 2. Promoting fibroblast (HSF cell line) and keratinocyte (HaCaT cell line) growth and migrating. | [ | |
| Other tissue engineering | N, N, N-trimethyl chitosan chloride (TMC) modified with pDNA- | 1. TMC 2. pDNA- | pDNA- | Enhancing the angiogenesis. | [ |
| Scaffolds containing both pDNA- | 1. Scaffolds (e.g., collagen-heparin scaffolds) 2. pDNA- | pDNA- | Enhancing the angiogenesis. | [ | |
| Aptamer-conjugated hydroxyapatite (Apt-HA) | Apt-HA | Apt-HA | Promoting angiogenesis and bone regeneration. | [ | |
| TDNs | TDNs | TDNs | 1. Promoting angiogenesis in vitro and the model of the jaw bisphosphonate-related osteonecrosis. 2. Facilitating the corneal wound healing, promoting the re-epithelialization of wounds, and improving the corneal transparency. 3. Preventing retina ischemia-reperfusion injury from the oxidative. 4. TDNs could induce the immune tolerance and prevent the onset of Type 1 diabetes. | [ | |
| PEI-DNA nanoparticles | 1. PEI 2. Genomic DNA | Genomic DNA | Delivering corneal gene for the corneal gene therapy. | [ | |
| DNA-based carrier systems | DNA nanoparticles | DNA nanoparticles | Ophthalmic drug delivery. | [ | |
| AuNPs-encoding pDNA | 1. AuNPs 2. pDNA | pDNA | Transfecting human retinal pigment epithelium cells. | [ |
Fig. 2The fate of DNA materials following delivery into cells. Nucleic acid nanomaterials (e.g., TDNs, pDNA, ssDNA, and dsDNA) with the excellent ability to enter cells, can be internalized by cells and degraded by lysosomal. Nucleic acid cargos combine the DNA materials and different delivery systems. These vectors can protect the DNA materials from degradation and promote cellular internalization. When inside the cells, these vector-DNA material complexes are embedded in an endosome, and these vectors can help DNA materials to escape lysosomal degradation
Fig. 3DNA-based nanostructures on tumor therapy by modification with drug, aptamer, or other functional ligands act various biological functions, which can bind to the target protein of cells. DNA-based nanostructures could distinguish cancer cells via ligand-receptor binding and permeate the membranes through endocytosis. The corresponding release of therapeutical agents would cause cellular damage and lead to apoptosis of cancer cells
DNA-based nanostructures on tumor therapy and cell imaging
| Number | DNA-based nanostructures | Proteins or aptamers /target | Modification type | Payloads | Loading way | Application | References |
|---|---|---|---|---|---|---|---|
| 1 | Straight and twisted DNA tubes, DNA triangle | N/A | N/A | DOX | Intercalation | Cancer therapy | [ |
| 2 | TDNs | FA/folate receptor | Click chemistry | DOX | Intercalation | Cancer therapy | [ |
| 3 | DNA tube | AS1411/NCL | Linkage at the ends | Thrombin | conjugating through cross-linkers | NCL-overexpressed cancer therapy | [ |
| 4 | DNA icosahedron | MUC1 aptamer /MUC1 | Chemical bond | DOX | Intercalation | MUC-positive cancer therapy | [ |
| 5 | DNA dendrimer | AS1411/NCL + MUC1 aptamer /MUC1 + ATP aptamer/ ATP | Chemical bonds | EPI | Intercalation | Cancer therapy | [ |
| 6 | TDNs | HApt /HER2 | Chemical bond | N/A | N/A | HER2-positive cancer therapy | [ |
| 7 | TDNs | Affibody/HER2 | Chemical bond | DOX | Intercalation | HER2-positive cancer therapy | [ |
| 8 | TDNs | AS1411 /NCL | Chemical bond | 5-FU | Chemical bond | NCL-overexpressed cancer therapy | [ |
| 9 | TDNs | SL28 /VEGF-165 + FA /folate receptor | click chemistry | DOX | intercalation | Colorectal cancer therapy | [ |
| 10 | TDNs | MUC1 aptamer /MUC1 + AS1411 /NCL | Extend from vertex + overhang on vertex | DOX | Intercalation | Cancer therapy and cell imaging | [ |
| 11 | TDNs | AS1411 /NCL + GS24 /TRF | Chemical bond | TMZ | Load | Glioblastoma therapy | [ |
| 12 | TDNs | AS1411/NCL + MUC1 aptamer/MUC1 | chemical bond | Ir | Load | Glioma therapy | [ |
| 13 | TDNs | N/A | N/A | MB | Interaction | Cancer therapy | [ |
| 14 | DNA triangle | N/A | N/A | BMEPC | Interaction | Cancer therapy | [ |
| 15 | TDNs | Nuclear localization peptide /nucleus | Chemical modification | ASOs | Disulfide linkage | Gene | [ |
| 16 | X-Y-shaped DNA | Sgc8/ CCRF-CEM cancer cells | Linked with Y-shaped DNA strand | DOX | Intercalation | T cell acute lymphoblastic leukemia therapy and MDR | [ |
| 17 | DNA nanotrain | Sgc8/ CCRF-CEM cancer cells or AS1411/NCL | Chimeric aptamer-trigger | DOX, EPI or daunorubicin | Intercalation | Targeted cancer theranostic | [ |
| 18 | NFs | Sgc8c /PTK7 | Integrated with template sequence | DOX | Intercalation | PTK7-overexpressed cancer therapy | [ |
| 19 | DNA nanocircuit | Aptamer/cancer cells | Linked with an overhung catalyst sequence | Chlorin e6 | Modified on ssDNA | Cancer therapy | [ |
| 20 | DNA nanocentipede | Zy1/ hepatoma SMC-7721 cells | Streptavidin-based linkage | DOX | Intercalation | Hepatoma cells SMC-7721 targeted delivery | [ |
| 21 | DNA nanorod | N/A | N/A | DOX | Intercalation | MDR | [ |
| 22 | NFs | N/A | N/A | DOX | Intercalation | MDR | [ |
| 23 | TDNs | N/A | N/A | DOX | Intercalation | MDR | [ |
| 24 | DNA triangle and tube | N/A | N/A | DOX | Intercalation | MDR | [ |
| 25 | TDNs | N/A | N/A | PTX | load | MDR | [ |
| 26 | TDNs, square, pentagon-based pyramid and prism | PfLDH aptamer /PfLDH | Linked with ssDNA | N/A | N/A | Malaria diagnosis | [ |
| 27 | TDNs | ANG /LPR-1 | Click chemistry | N/A | N/A | Brain tumor imaging | [ |
| 28 | TDNs | FAM and HE | Amido bond | N/A | N/A | H + and O[ | [ |
Fig. 4DNA-based nanostructures on immunostimulatory reactions. CpG-modified DNA-based nanostructures could enter immune cells, including macrophages, mast, dendritic and monocyte cells through integrating with TLR9, which subsequently induce cascade reactions and promote the secretion of remarkable cytokines and chemokines
Fig. 5DNA-based nanostructures on bioimaging and diagnosis. Targeted ligands (e.g., affibody, peptides and aptamers) and cargoes (e.g., drugs, fluorescein and radioisotopes) were simultaneously attached to DNA-based nanostructures. After specific combination with biomarkers, the integrates entered target cells and released fluorescent labels to sensitively detect the diseased regions